Literature DB >> 30738636

An in vitro long-term study of cryopreserved umbilical cord blood-derived platelet-rich plasma containing growth factors-PDGF-BB, TGF-β, and VEGF.

Kyoko Baba1, Yasuharu Yamazaki2, Yumiko Sone2, Yoshika Sugimoto2, Kazuno Moriyama2, Takayuki Sugimoto2, Kennichi Kumazawa2, Yasuhito Shimakura2, Akira Takeda2.   

Abstract

PURPOSE: Umbilical cord blood-derived platelet-rich plasma (UCB-PRP) containing growth factors has attracted attention as a biomaterial useful for regenerative medicine. The osteoblastic differentiation of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) can be induced by UCB-PRP.
MATERIALS AND METHODS: Nine samples of UC and UCB were used to conduct an in vitro study that determined the contents of three growth factors (i.e., platelet-derived growth factor, transforming growth factor β-1, and vascular endothelial growth factor) and that examined, by staining with Alizarin red, their ability to induce the osteoblastic differentiation of UC-MSCs at the baseline, 3 months, and 3 years of cryopreservation.
RESULTS: The contents of growth factors in cryopreserved UCB-PRP were markedly elevated compared to those found in UCB at baseline. The samples of UCB that were added with cryopreserved UCB-PRP and those with bone morphogenetic protein-2 were stained granularly with Alizarin red, thus indicating the presence of calcium. The samples of UCB that were not added with UCB-PRP were not stained with Alizarin red. The above-mentioned contents and ability were maintained at 3 years of cryopreservation. Cryopreserved UCB-PRP possibly and advantageously induced the osteoblastic differentiation of UC-MSCs.
CONCLUSION: The potential clinical application of cryopreserved UCB-PRP to regenerative medicine was suggested.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cryopreservation; Growth factor; Mesenchymal stromal cells; Platelet-rich plasma; Regenerative medicine; Umbilical cord blood

Mesh:

Substances:

Year:  2019        PMID: 30738636     DOI: 10.1016/j.jcms.2019.01.020

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  2 in total

1.  Efficacy of Platelet-Rich Plasma in the Treatment of Fractures: A Meta-Analysis.

Authors:  Zhu Xu; Han Hu; Bin Wu; Chenglong Huang; Qin Liu; Bin Chen
Journal:  Comput Math Methods Med       Date:  2022-06-02       Impact factor: 2.809

2.  Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine.

Authors:  Dinara Samarkanova; Steven Cox; Diana Hernandez; Luciano Rodriguez; Ricardo P Casaroli-Marano; Alejandro Madrigal; Sergio Querol
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.